{"id":"crizotinib-capsules","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Vision disorders (blurred vision, diplopia)"},{"rate":"40-50","effect":"Gastrointestinal toxicity (nausea, vomiting, diarrhea)"},{"rate":"30-40","effect":"Edema (peripheral, facial)"},{"rate":"25-35","effect":"Fatigue"},{"rate":"20-30","effect":"Elevated transaminases"},{"rate":"5-10","effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL601719","moleculeType":"Small molecule","molecularWeight":"450.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Crizotinib selectively inhibits ALK and ROS1 receptor tyrosine kinases, which are often aberrantly activated in certain cancers through chromosomal translocations. By blocking these kinases, the drug prevents downstream signaling that drives proliferation and survival of ALK-positive or ROS1-positive tumor cells. This targeted approach is particularly effective in non-small cell lung cancers harboring ALK or ROS1 fusions.","oneSentence":"Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:53.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"ALK-positive metastatic non-small cell lung cancer"},{"name":"ROS1-positive metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT02838420","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-08-03","conditions":"Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer","enrollment":187},{"nctId":"NCT04603807","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":220},{"nctId":"NCT03194893","phase":"PHASE3","title":"A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Neoplasms","enrollment":200},{"nctId":"NCT03052608","phase":"PHASE3","title":"A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-04-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":296},{"nctId":"NCT03620643","phase":"PHASE2","title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2019-05-09","conditions":"Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer","enrollment":33},{"nctId":"NCT03596866","phase":"PHASE3","title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-04-19","conditions":"ALK+ Advanced NSCLC","enrollment":248},{"nctId":"NCT02075840","phase":"PHASE3","title":"A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-19","conditions":"Non-Small Cell Lung Cancer","enrollment":303},{"nctId":"NCT03375242","phase":"","title":"Safety and Efficacy of Xalkori ROS1","status":"RECRUITING","sponsor":"Pfizer","startDate":"2017-10-25","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT01828112","phase":"PHASE3","title":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06-28","conditions":"Non-Small Cell Lung Cancer","enrollment":231},{"nctId":"NCT00828919","phase":"NA","title":"Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-03-07","conditions":"Solid Tumors","enrollment":52},{"nctId":"NCT06569420","phase":"PHASE3","title":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2021-12-31","conditions":"Non-Small Cell Lung Cancer, ALK-positive, SAF-189s","enrollment":275},{"nctId":"NCT03546894","phase":"","title":"A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-23","conditions":"Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung","enrollment":111},{"nctId":"NCT02473497","phase":"","title":"Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Neoplasm","enrollment":""},{"nctId":"NCT04211922","phase":"PHASE2","title":"Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib","status":"TERMINATED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-01-21","conditions":"ALK-positive Non-small Cell Lung Cancer","enrollment":4},{"nctId":"NCT06254599","phase":"PHASE3","title":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-05-01","conditions":"Non-small Cell Lung Cancer","enrollment":255},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT01524926","phase":"PHASE2","title":"CREATE: Cross-tumoral Phase 2 With Crizotinib","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-09","conditions":"Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1","enrollment":582},{"nctId":"NCT02223819","phase":"PHASE2","title":"Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-03","conditions":"Uveal Melanoma","enrollment":34},{"nctId":"NCT04632758","phase":"PHASE3","title":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer","enrollment":292},{"nctId":"NCT03215693","phase":"PHASE2","title":"X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2017-09-28","conditions":"Non-Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT02584634","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2015-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":43},{"nctId":"NCT05204628","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib","status":"UNKNOWN","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-02-07","conditions":"Non-small Cell Lung Cancer","enrollment":238},{"nctId":"NCT04856293","phase":"PHASE1","title":"Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-04-16","conditions":"Healthy Participants","enrollment":25},{"nctId":"NCT01999972","phase":"PHASE1","title":"A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-02-26","conditions":"Advanced Solid Tumors","enrollment":50},{"nctId":"NCT02336451","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-01","conditions":"ALK-positive Non-small Cell Lung Cancer","enrollment":156},{"nctId":"NCT01597258","phase":"","title":"Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05-29","conditions":"Non-small Cell Lung Cancer","enrollment":2029},{"nctId":"NCT01685138","phase":"PHASE2","title":"LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-20","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT01801111","phase":"PHASE1, PHASE2","title":"A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-06-20","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":138},{"nctId":"NCT03707847","phase":"PHASE4","title":"Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2018-10-01","conditions":"ALK-Positive Anaplastic Large Cell Lymphoma","enrollment":20},{"nctId":"NCT01871805","phase":"PHASE1, PHASE2","title":"A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-30","conditions":"Non-Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT01685060","phase":"PHASE2","title":"LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11-26","conditions":"Non-Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT02006277","phase":"PHASE1","title":"A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12","conditions":"Healthy","enrollment":21},{"nctId":"NCT01549574","phase":"PHASE1","title":"Drug Drug Interaction Study Of Crizotinib With Esomeprazole.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05","conditions":"Healthy","enrollment":16},{"nctId":"NCT01297595","phase":"PHASE1","title":"Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03","conditions":"Healthy","enrollment":22},{"nctId":"NCT01441388","phase":"PHASE1","title":"A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2011-12","conditions":"Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular","enrollment":""},{"nctId":"NCT01154218","phase":"PHASE1","title":"Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00939731","phase":"PHASE1","title":"Relative Drug Exposures Of Two Formulations of PF-02341066","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xalkori"],"phase":"phase_3","status":"active","brandName":"Crizotinib Capsules","genericName":"Crizotinib Capsules","companyName":"Shouyao Holdings (Beijing) Co. LTD","companyId":"shouyao-holdings-beijing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth. Used for ALK-positive metastatic non-small cell lung cancer, ROS1-positive metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}